Clinical trial
A Phase 4, Open-Label, Single-Arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes.
NCT01201811 is registered in ClinicalTrials.gov with Celgene as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 4, Open-Label, Single-Arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes.
- Lead sponsor
- Celgene
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- October 1, 2010
- Completion date
- May 1, 2013
- Enrollment
- 44 (actual)
- Sites
- 11
Conditions
As the registry lists them; a condition with its own page is linked.